A 68-year-old man from Mumbai with a 15-year history of type 2 diabetes presents with fatigue, bone pain, and recurrent kidney stones. Serum calcium is 9.8 mg/dL (normal 8.5–10.5), phosphate is 3.2 mg/dL (normal 2.5–4.5), PTH is 185 pg/mL (normal 15–65), and 25-hydroxyvitamin D is 18 ng/mL (normal >30). Creatinine is 2.1 mg/dL (eGFR 28 mL/min/1.73 m²). What is the most likely mechanism driving the elevated PTH in this patient?

Explanation

## Mechanism of Secondary Hyperparathyroidism in CKD ### Clinical Context: Stage 3b CKD with Mineral Bone Disease | Parameter | Patient Value | Normal Range | Interpretation | |-----------|---------------|--------------|----------------| | Creatinine | 2.1 mg/dL | 0.7–1.3 | **Elevated** | | eGFR | 28 mL/min/1.73 m² | >60 | **Stage 3b CKD** | | Serum Ca | 9.8 mg/dL | 8.5–10.5 | **Low-normal (relative hypocalcemia)** | | Serum PO₄ | 3.2 mg/dL | 2.5–4.5 | **High-normal (early retention)** | | PTH | 185 pg/mL | 15–65 | **Markedly elevated (secondary response)** | | 25-OH Vitamin D | 18 ng/mL | >30 | **Deficient** | **Key Point:** In secondary hyperparathyroidism, PTH rises as a **compensatory mechanism** to maintain calcium homeostasis in the face of declining renal function. This is fundamentally different from primary hyperparathyroidism, where PTH is autonomously elevated. ### Pathophysiology: The CKD-Mineral Bone Disease Cascade ```mermaid flowchart TD A[Declining GFR < 45 mL/min]:::outcome --> B[Phosphate retention] B --> C[Hyperphosphatemia]:::outcome A --> D[Reduced 1,25-dihydroxyvitamin D synthesis] D --> E[Hypocalcemia]:::outcome C --> F[FGF23 surge] F --> G[Further suppression of 1,25-OH-D] E --> H[Parathyroid hyperplasia] H --> I[Elevated PTH]:::action I --> J[Increased urinary phosphate excretion] J --> K{Compensation successful?} K -->|Early CKD| L[Calcium normalized]:::outcome K -->|Late CKD| M[Persistent hypocalcemia + high PTH]:::urgent C -.->|Stimulates| H E -.->|Stimulates| H ``` **High-Yield:** The **two-hit mechanism** of secondary hyperparathyroidism: 1. **Phosphate retention** → direct stimulation of PTH secretion 2. **Vitamin D deficiency** → reduced suppression of PTH + hypocalcemia → further PTH stimulation ### Why This Is Secondary, Not Primary or Tertiary **Clinical Pearl:** The **serum calcium is low-normal (9.8 mg/dL)**, not elevated. In primary hyperparathyroidism, PTH is elevated *because* calcium is high; the parathyroids are responding inappropriately to normal/high calcium. Here, PTH is elevated *because* calcium is low — a physiologically appropriate response. **Mnemonic: SHPT vs PHPT vs THPT** - **SHPT (Secondary):** PTH ↑ due to renal disease/vitamin D deficiency; Ca ↓ or low-normal; PO₄ ↑; **appropriate response** - **PHPT (Primary):** PTH ↑ due to parathyroid adenoma/hyperplasia; Ca ↑; **autonomous secretion** - **THPT (Tertiary):** PTH ↑ and Ca ↑ after long-standing SHPT; parathyroids become autonomous; occurs post-renal transplant ### Why NOT Primary Hyperparathyroidism? In primary hyperparathyroidism: - Serum calcium would be **elevated** (>10.5 mg/dL), not low-normal - Phosphate would be **low** (due to PTH-induced urinary phosphate wasting), not high-normal - The clinical context (CKD, vitamin D deficiency) does not fit ### Why NOT Tertiary Hyperparathyroidism? Tertiary hyperparathyroidism occurs when: - A patient with long-standing secondary hyperparathyroidism receives a renal transplant - The parathyroids become **autonomous** and continue secreting PTH despite restoration of renal function - Serum calcium becomes **elevated** (hypercalcemia develops) This patient still has CKD stage 3b (eGFR 28), not a transplant recipient, and calcium is low-normal, not elevated. ### Management of Secondary Hyperparathyroidism 1. **Phosphate control:** Dietary restriction + phosphate binders (calcium-based or non-calcium: sevelamer, lanthanum) 2. **Vitamin D repletion:** Cholecalciferol (vitamin D₂/D₃) to raise 25-OH-D above 30 ng/mL 3. **Active vitamin D:** Calcitriol (1,25-OH-D) if PTH remains elevated despite phosphate/vitamin D correction 4. **Calcimimetics:** Cinacalcet (allosteric activator of calcium-sensing receptor) if PTH >300 pg/mL and refractory to above 5. **Monitor:** Calcium, phosphate, PTH, alkaline phosphatase, and bone imaging (DEXA, bone biopsy if indicated) **Warning:** Avoid excessive calcium supplementation in CKD — increases vascular calcification risk. Prefer non-calcium phosphate binders.